The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
Open accessAbstract
Purpose: Bosutinib is a potent dual SRC/ABL kinase inhibitor approved for adults with Philadelphia chromosome–positive chronic myeloid leukemia (CML) resistant and /or intolerant to prior therapy. We assessed the efficacy and safety of bosutinib versus imatinib for first-line treatment of chronic-phase CML. Methods: In this ongoing, multinational, phase III study, 536 patients with newly diagnosed chronic-phase CML were randomly assigned 1:1 to receive 400 mg of bosutinib once daily (n = 268) or imatinib (n = 268). Per protocol, efficacy was assessed in patients who were Philadelphia chromosome–positive with typical (e13a2/e14a2) transcripts (bosutinib, n = 246; imatinib, n = 241). Patients with Philadelphia chromosome–negative–/ BCR-ABL1–positive status and those with unknown Philadelphia chromosome status and/or atypical BCR-ABL1 transcript type were excluded from this population. Results: The major molecular response (MMR) rate at 12 months (primary end point) was significantly higher with bosutinib versus imatinib (47.2% v 36.9%, respectively; P = .02), as was complete cytogenetic response (CCyR) rate by 12 months (77.2% v 66.4%, respectively; P = .0075). Cumulative incidence was favorable with bosutinib (MMR: hazard ratio, 1.34; P = .0173; CCyR: hazard ratio, 1.38; P < .001), with earlier response times. Four patients (1.6%) receiving bosutinib and six patients (2.5%) receiving imatinib experienced disease progression to accelerated/blast phase. Among treated patients, 22.0% of patients receiving bosutinib and 26.8% of patients receiving imatinib discontinued treatment, most commonly for drug-related toxicity (12.7% and 8.7%, respectively). Grade ≥ 3 diarrhea (7.8% v 0.8%) and increased ALT (19.0% v 1.5%) and AST (9.7% v 1.9%) levels were more common with bosutinib. Cardiac and vascular toxicities were uncommon. Conclusion: Patients who received bosutinib had significantly higher rates of MMR and CCyR and achieved responses faster than those who received imatinib. Consistent with the known safety profile, GI events and transaminase elevations were more common with bosutinib. Results indicate bosutinib may be an effective first-line treatment for chronic-phase CML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Baccarani, M., Deininger, M. W., Rosti, G., Hochhaus, A., Soverini, S., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Guilhot, F., et al. (2013) · Blood · doi:10.1182/blood-2013-05-501569 · Cited by 1,987
Self-citationLong-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
Hochhaus, A., Larson, R. A., Guilhot, F., Radich, J. P., Branford, S., Hughes, T. P., Baccarani, M., Deininger, M. W., Cervantes, F., Fujihara, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609324 · Cited by 1,285
Self-citationCortes, J. E., Saglio, G., Kantarjian, H. M., Baccarani, M., Mayer, J., Boqué, C., Shah, N. P., Chuah, C., Casanova, L., Bradley-Garelik, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.8899 · Cited by 947
Self-citationBower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Hochhaus, A., Saglio, G., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P. D., Etienne, G., Dorlhiac-Llacer, P. E., Clark, R. E., et al. (2016) · Leukemia · doi:10.1038/leu.2016.5 · Cited by 839
Self-citationCortes, J. E., Kim, D.-W., Kantarjian, H. M., Brümmendorf, T. H., Dyagil, I., Griskevicius, L., Malhotra, H., Powell, C., Gogat, K., Countouriotis, A. M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7522 · Cited by 466
Self-citationCortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D.-W., Turkina, A. G., Shen, Z.-X., Pasquini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 463
Self-citationGambacorti-Passerini, C., Antolini, L., Mahon, F.-X., Guilhot, F., Deininger, M., Fava, C., Nagler, A., Della Casa, C. M., Morra, E., Abruzzese, E., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr060 · Cited by 429
Self-citationActivity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C., & Boschelli, F. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8853 · Cited by 399
Self-citationCross, N. C. P., White, H. E., Colomer, D., Ehrencrona, H., Foroni, L., Gottardi, E., Lange, T., Lion, T., Machova Polakova, K., Dulucq, S., et al. (2015) · Leukemia · doi:10.1038/leu.2015.29 · Cited by 336
Self-citation
Cited by
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547
Self-citationKinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D., & Jänne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,024
Properties of FDA-approved small molecule protein kinase inhibitors
Roskoski, R. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.03.006 · Cited by 554
Zhu, C., Wei, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1090-3 · Cited by 488
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Metadata
- Authors
- Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D.-W., Dyagil, I., Glushko, N., Milojkovic, D., le Coutre, P., Garcia-Gutierrez, V., Reilly, L., Jeynes-Ellis, A., Leip, E., Bardy-Bouxin, N., Hochhaus, A., & Brümmendorf, T. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-01-20
- Volume
- 36
- Issue
- 3
- Pages
- 231-237
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2766187515
- Cited by
- 495
- References
- 18
- FWCI
- 28.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. https://app.cochat.ai/papers/10.1200/jco.2017.74.7162
- The paper
- Cortes, J. E., Gambacorti-Passerini, C., Deininger, M. W., Mauro, M. J., Chuah, C., Kim, D.-W., Dyagil, I., Glushko, N., Milojkovic, D., le Coutre, P., Garcia-Gutierrez, V., Reilly, L., Jeynes-Ellis, A., Leip, E., Bardy-Bouxin, N., Hochhaus, A., & Brümmendorf, T. H. (2018). Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2017.74.7162
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.